$LUNG

Lehman David Aaron sold $8K of LUNG

Lehman David Aaron (GENERAL COUNSEL) sold 4,915 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Original reporting
SEC EDGAR · Lehman David Aaron
Published Jun 3, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The disclosure provides a datapoint on insider behavior but does not introduce new company performance, regulatory, or product developments.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a fundamental re-rating.

03

What to watch

Form 4s often reflect diversification, tax, or pre-planned personal needs; without context on total holdings or prior sales, signal strength is limited.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-03 after the sale on 2026-06-01

Background

The filing is an SEC Form 4 insider transaction disclosure for Pulmonx Corp.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

Pulmonx Corp insider (general counsel) sold 4,915 shares in an open-market transaction at $1.54 on 2026-06-01.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to near-term sentiment/flow effects.

Evidence & confidence

This is an SEC Form 4 disclosure with transaction size and price, but no accompanying company-specific news (earnings, guidance, trial, deal).

Market effects

Minimal; single-company insider transaction without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/compensation-related and not a bearish view, especially with no 10b5-1 plan disclosed.

Key entities

  • Pulmonx Corp

    Subject of the insider transaction disclosure (LUNG).

  • Lehman David Aaron

    General counsel who sold 4,915 shares on 2026-06-01.

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu